Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$68.48 - $81.09 $51,839 - $61,385
-757 Reduced 14.29%
4,541 $326,000
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $21 - $12,524
163 Added 3.17%
5,298 $376,000
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $203,989 - $224,663
-2,809 Reduced 35.36%
5,135 $379,000
Q1 2022

May 13, 2022

SELL
$61.48 - $73.72 $733,333 - $879,332
-11,928 Reduced 60.02%
7,944 $580,000
Q4 2021

Feb 10, 2022

SELL
$53.63 - $62.52 $779,726 - $908,978
-14,539 Reduced 42.25%
19,872 $1.24 Million
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $695,010 - $814,115
11,746 Added 51.82%
34,411 $2.04 Million
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $413,063 - $449,826
-6,672 Reduced 22.74%
22,665 $1.51 Million
Q1 2021

May 12, 2021

BUY
$59.34 - $66.74 $358,650 - $403,376
6,044 Added 25.95%
29,337 $1.85 Million
Q4 2020

Feb 16, 2021

BUY
$57.74 - $65.43 $157,687 - $178,689
2,731 Added 13.28%
23,293 $1.45 Million
Q3 2020

Nov 16, 2020

BUY
$57.43 - $63.64 $412,749 - $457,380
7,187 Added 53.73%
20,562 $1.24 Million
Q2 2020

Jul 31, 2020

SELL
$54.82 - $64.09 $74,007 - $86,521
-1,350 Reduced 9.17%
13,375 $786,000
Q1 2020

May 07, 2020

BUY
$46.4 - $67.43 $683,240 - $992,906
14,725 New
14,725 $821,000
Q4 2019

Jan 23, 2020

SELL
$49.21 - $64.19 $263,962 - $344,315
-5,364 Closed
0 $0
Q3 2019

Nov 01, 2019

BUY
$42.77 - $50.71 $30,067 - $35,649
703 Added 15.08%
5,364 $272,000
Q3 2018

Nov 13, 2018

SELL
$55.19 - $62.25 $16,557 - $18,675
-300 Reduced 6.05%
4,661 $289,000
Q3 2017

Nov 14, 2017

BUY
$55.23 - $63.74 $273,996 - $316,214
4,961
4,961 $316,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $124B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Premier Asset Management LLC Portfolio

Follow Premier Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Premier Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Premier Asset Management LLC with notifications on news.